Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Correction

Following publication of the original article [1], the authors reported errors in the formatting of the table. The details of the errors are as follows:

In Table 1, the data presented do not correspond to the row title:

• The education row currently contains incorrect data.

• The weight row currently contains the years of education.

• The APOEε4 genotype row currently contains the weight data.

In Table 1, the data should be displayed as follows:

Variable

Intention-to-treat population (n = 797)

Placebo

(n = 266)

Gantenerumab

105 mg

(n = 271)

Gantenerumab

225 mg

(n = 260)

Age, years, mean (SD)

69.5 (7.5)

70.3 (7.0)

71.3 (7.1)

Education, years, mean (SD)

12.6 (4.3)

12.9 (4.8)

12.1 (4.5)

Weight, kg, mean (SD)

69.8 (12.9)

70.5 (13.6)

70.1 (12.5)

APOEε4 genotype, %^a